What is SS-31 in research contexts?

SS-31 (elamipretide) is a synthetic four-amino-acid Szeto-Schiller tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane. It is studied in preclinical research for cristae stabilization, mitochondrial bioenergetics, and ischemia-reperfusion injury.

How does SS-31 address mitochondrial aging?

Aging is associated with cardiolipin loss, cristae deterioration, and reduced mitochondrial bioenergetics. SS-31 binds cardiolipin selectively, stabilizing inner mitochondrial membrane structure and improving age-associated mitochondrial dysfunction in cardiac, brain, kidney, and muscle research models.

What aging endpoints are measured in SS-31 research?

Endpoints include sarcopenia markers (muscle mass, strength), cardiac function on echocardiography, cognitive performance, kidney function decline, integrated frailty assessment, and lifespan in chronic dosing studies in aged rodent cohorts.

Is SS-31 approved for human use?

No. SS-31 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

Where can researchers source third-party tested SS-31?

Midwest Peptide supplies research-grade SS-31 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

SS-31 Aging: Mitochondrial Decline Research

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Free shipping on every orderFree shipping on every order

5% off when you pay with ZelleSave an extra 5% when you pay with Zelle

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

SS-31 Aging: Mitochondrial Decline Research | Midwest Peptide

For Research Use Only. SS-31 is intended exclusively for in vitro and preclinical research. It is not approved for human use, is not a drug, and should never be administered to humans or to animals outside of an authorized research protocol.

The Mitochondrial Decline Framework in Aging Research

The mitochondrial decline framework is one of the foundational concepts in aging biology research. Documented features include progressive declines in mitochondrial respiratory capacity across tissues, structural deterioration of cristae architecture in aged mitochondria, increased ROS production from age-related electron transport chain dysfunction, accumulation of oxidative damage to mitochondrial DNA and proteins, and reduced bioenergetic capacity that limits the cellular response to stress. These features have been documented across multiple species including mice, rats, primates, and human tissues, providing a cross-species foundation for aging research.

The framework predicts that interventions which preserve or restore mitochondrial function should benefit aged tissue, since the loss of mitochondrial capacity is causally connected to many of the functional declines that characterize aging. SS-31 fits naturally into this framework because the mechanism (cardiolipin protection, cristae stabilization, supercomplex preservation) addresses several of the structural and functional features that decline with age.

The Nature subject hub on aging and the ScienceDirect topic page on mitochondrial aging archive primary research on the aging mitochondrial decline framework relevant to the SS-31 literature.

Cristae Architecture in Aged Tissue

A central structural feature of aging mitochondria is the deterioration of cristae architecture. Aged mitochondria across multiple tissues show reduced cristae density, disorganized cristae folding, and partial loss of the supramolecular structure that supports respiratory chain assembly. The structural deterioration is mechanistically linked to the functional decline because cristae integrity is required for efficient electron transport and oxidative phosphorylation.

Published SS-31 research in aging models documents preserved cristae architecture in aged tissue, with electron microscopy showing maintained cristae density and consistent cristae folding compared with untreated aged controls. The structural preservation is mechanistically tied to the cardiolipin protection that prevents the cardiolipin peroxidation which drives age-related cristae remodeling. For an extended discussion of the mechanism, see our companion article on SS-31 mechanism of action and cardiolipin binding research.

Skeletal Muscle Aging Research

Skeletal muscle is one of the most studied tissues in aging research because of the clinical importance of age-related muscle decline (sarcopenia) and the relative accessibility of muscle tissue for biopsy and analysis. Aged skeletal muscle shows characteristic features including reduced mitochondrial density, decreased respiratory capacity, increased ROS production, and progressive loss of muscle mass and function. The mitochondrial features are causally connected to the functional decline through the energetic limitation of muscle performance.

Published SS-31 research in skeletal muscle aging models documents preserved mitochondrial function in aged muscle, restored respiratory capacity in older animals, and improved functional endpoints in animal-model studies. The skeletal muscle research is one of the more actively studied areas in the aging SS-31 literature because the endpoints (mitochondrial function, muscle performance, fiber type composition) connect mechanism to function in an integrated way.

The Cell Press journal Cell Reports archives primary research on skeletal muscle aging relevant to the SS-31 literature.

Cardiac Aging Research

Cardiac aging research overlaps with the cardiac SS-31 literature covered in our companion article on SS-31 cardiac research and ischemia-reperfusion studies, but the aging framework adds distinct elements. Aged cardiomyocytes show progressive declines in mitochondrial function, increased susceptibility to ischemic injury, and altered responses to cardiac stress. The cumulative mitochondrial decline contributes to the age-related increase in cardiovascular vulnerability that characterizes aged populations.

Published SS-31 research in cardiac aging models documents preserved mitochondrial function in aged cardiac tissue, reduced age-related declines in cardiac performance, and improved tolerance to cardiac stress in older animals. The cardiac aging research informs the broader cardiac literature by addressing the chronic dimension of cardiac mitochondrial protection.

Kidney Aging Research

Kidney function declines progressively with age across mammalian species, with the kidney showing one of the most pronounced age-related functional declines of any organ system. The mitochondrial decline framework is mechanistically relevant to kidney aging because tubular cells (which perform most of the energy-intensive solute reabsorption) have high mitochondrial density and depend on oxidative phosphorylation. Age-related mitochondrial dysfunction in tubular cells contributes to the decline in kidney function.

Published SS-31 research in kidney aging models documents preserved tubular function in aged animals, reduced age-related fibrosis markers, and improved overall kidney function endpoints. The kidney aging research complements the broader SS-31 renal literature by addressing the chronic dimension of kidney mitochondrial protection.

Brain and Cognitive Aging Research

Brain aging is characterized by progressive declines in cognitive function, with mitochondrial dysfunction contributing through several pathways. Neurons depend on mitochondrial function for synaptic transmission and the energy-intensive process of maintaining ion gradients. Age-related mitochondrial dysfunction in neurons reduces the energy supply available for synaptic function and increases ROS-related damage to neuronal components. The cumulative effect contributes to age-related cognitive decline and to the increased vulnerability to neurodegenerative disease.

Published SS-31 research in brain aging models documents preserved mitochondrial function in aged brain tissue, improved cognitive endpoints in some animal-model designs, and reduced markers of age-related neuronal stress. The brain aging research is methodologically diverse and the endpoint framework is more complex than for peripheral tissues, but the cumulative literature documents mechanism-relevant effects.

The Frontiers in Aging Neuroscience archives primary research on brain aging relevant to the SS-31 literature.

Comparison with Other Aging Research Compounds

The aging SS-31 research connects to a broader landscape of research compounds that engage aging biology through different mechanisms. The NAD+ research cluster covers the central coenzyme of mitochondrial metabolism that operates through redox cycling and substrate availability for sirtuin and PARP enzymes. NAD+ levels decline with age in multiple tissues, and NAD+ research includes longevity endpoints in animal-model studies covered in NAD+ longevity studies.

The MOTS-C research cluster covers the mitochondrially encoded peptide that operates through metabolic signaling and AMPK activation. MOTS-C declines with age in some tissues and represents a different mechanistic approach to mitochondrial aging biology. For an extended SS-31 versus MOTS-C comparison, see our companion article on SS-31 vs MOTS-C mitochondrial peptide comparison research.

The glutathione research cluster covers the master antioxidant tripeptide that addresses the oxidative dimension of aging biology through redox cycling. Each of these research compounds engages aging through complementary mechanisms, and research designs that include multiple compounds in matched conditions characterize the distinct contributions of each mechanism to integrated aging endpoints.

Cellular Senescence and Mitochondrial Dysfunction

Cellular senescence is a state of growth arrest associated with multiple aging hallmarks including mitochondrial dysfunction. Senescent cells show altered mitochondrial morphology, reduced respiratory capacity, increased ROS production, and the secretion of inflammatory factors collectively called the senescence-associated secretory phenotype (SASP). The mitochondrial features of senescence overlap with the broader mitochondrial decline framework, and SS-31 effects on mitochondrial structural integrity may influence the senescence trajectory.

Published research on SS-31 in senescence models documents effects on mitochondrial features of senescent cells, with reduced ROS production and partially restored respiratory capacity in some experimental contexts. The senescence research is an active and growing area in the aging SS-31 literature and connects to the broader research on cellular senescence as a contributor to aging biology.

Cross-Species Aging Research

Aging SS-31 research has been conducted across multiple species, with rodent models providing the largest body of published data and other species (C. elegans, Drosophila, larger mammals) providing complementary findings. The cross-species literature documents broadly conserved aging mitochondrial features and broadly conserved SS-31 protective effects, with quantitative differences that reflect the distinct biology of each model organism. The cross-species consistency strengthens the cumulative aging literature by demonstrating that the mechanism is not specific to one model organism.

Research programs that work in multiple species benefit from understanding the species-specific aspects of the literature. Studies that report findings from a single species without context for cross-species generalization provide less actionable data than studies that explicitly discuss how their findings relate to the broader cross-species literature. The Wiley Online Library aging research collection archives primary research on cross-species aging biology relevant to the SS-31 literature.

Lifespan and Healthspan Endpoints

A subset of the aging SS-31 literature addresses lifespan and healthspan endpoints in animal-model studies. Lifespan endpoints measure the duration of life and require long-term experimental designs that can span months to years depending on the species. Healthspan endpoints measure the duration of healthy life and use functional measures (motor performance, cognitive function, organ function) that distinguish healthy aging from frail aging. Both endpoint types contribute to the cumulative aging literature.

Published SS-31 lifespan and healthspan work documents some lifespan extension in selected models and improved healthspan endpoints across multiple animal-model designs. The lifespan literature is methodologically demanding and the published data is smaller than for shorter-term endpoints, but the integrated aging research framework benefits from including these long-term endpoints alongside the shorter-term mechanism work.

Methodology Considerations for Aging Research

Aging SS-31 research is most informative when the methodology matches the aging framework. Cross-sectional aging designs compare young and aged animals to establish baseline aging effects, then introduce SS-31 to evaluate intervention effects. Longitudinal designs follow individual animals across time to characterize the trajectory of aging and the modification by SS-31. Each design contributes distinct information.

Endpoint selection should integrate mitochondrial mechanism endpoints (respiration, cristae architecture, ROS production) with tissue function endpoints (organ-specific functional measures) and integrated outcomes (healthspan, lifespan where feasible). Research that reports findings across multiple endpoint levels provides the most actionable cumulative data.

Reference compound quality matters particularly for aging research because the experimental designs are long-duration and any sourcing variability across the study compromises the cumulative interpretation. For sourcing considerations, see our companion article on where to buy SS-31 for research and the elamipretide sourcing guide.

Translation Across Aging Tissue Types

The aging SS-31 literature documents effects across multiple tissue types relevant to aging biology, including cardiac, skeletal muscle, kidney, brain, and other organ systems. The cross-tissue work documents that the cardiolipin-binding mechanism is broadly conserved across tissue types in aged animals, with the magnitude of effect on specific endpoints varying with tissue mitochondrial composition and the specific aging trajectory of the tissue. Research programs that include multiple tissue types in their aging design portfolio characterize the broader applicability of SS-31 to aging biology beyond a single tissue context.

The cross-tissue aging research also informs the broader question of which aging features are mitochondrially driven and which depend on other mechanisms. Tissues where SS-31 produces the largest aging effects (cardiac, skeletal muscle) tend to be tissues where mitochondrial function is particularly critical to baseline function. Tissues where the effects are smaller may have aging trajectories that depend more on non-mitochondrial mechanisms.

Open Questions in Aging SS-31 Research

Several open questions remain in aging SS-31 research. The dose-response relationship for chronic dosing in aging models is incompletely characterized in the public literature, with most published work using selected doses without systematic dose variation. The mechanism connection between mitochondrial protection and the broader aging hallmarks (telomere biology, epigenetic clocks, senescence burden) is incompletely resolved. The applicability of findings from intervention starting at middle age versus late age is also incompletely characterized.

These open questions create opportunities for new aging research that contributes to the cumulative literature. Research programs that include long-duration designs, multi-tissue endpoints, and integrated aging biology measurements alongside mitochondrial endpoints generate the most informative data for the aging mitochondrial decline framework.

Research Peptides Referenced

SS-31 10mg, research grade Szeto-Schiller mitochondrially targeted tetrapeptide
MOTS-C 10mg, comparator mitochondrial peptide for aging research
NAD+ 500mg, coenzyme that declines with age in research models
Glutathione 1500mg, antioxidant comparator for aging redox research

For complete sourcing details see the SS-31 sourcing guide.

Within the SS-31 cluster:

Related clusters:

Not for human consumption. Research use only.

Age Verification

SS-31 Aging Research: Mitochondrial Decline Studies

Frequently Asked Questions

What is SS-31 in research contexts?

How does SS-31 address mitochondrial aging?

What aging endpoints are measured in SS-31 research?

Is SS-31 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

The Mitochondrial Decline Framework in Aging Research

Cristae Architecture in Aged Tissue

Skeletal Muscle Aging Research

Cardiac Aging Research

Kidney Aging Research

Brain and Cognitive Aging Research

Comparison with Other Aging Research Compounds

Cellular Senescence and Mitochondrial Dysfunction

Cross-Species Aging Research

Lifespan and Healthspan Endpoints

Methodology Considerations for Aging Research

Translation Across Aging Tissue Types

Open Questions in Aging SS-31 Research

Research Peptides Referenced

Ready to Start Your Research?

Where can researchers source third-party tested SS-31?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

SS-31 Aging Research: Mitochondrial Decline Studies

Frequently Asked Questions

What is SS-31 in research contexts?

How does SS-31 address mitochondrial aging?

What aging endpoints are measured in SS-31 research?

Is SS-31 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

The Mitochondrial Decline Framework in Aging Research

Cristae Architecture in Aged Tissue

Skeletal Muscle Aging Research

Cardiac Aging Research

Kidney Aging Research

Brain and Cognitive Aging Research

Comparison with Other Aging Research Compounds

Cellular Senescence and Mitochondrial Dysfunction

Cross-Species Aging Research

Lifespan and Healthspan Endpoints

Methodology Considerations for Aging Research

Translation Across Aging Tissue Types

Open Questions in Aging SS-31 Research

Research Peptides Referenced

Related Research Reading

Ready to Start Your Research?

Where can researchers source third-party tested SS-31?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?